Solvent Selection for Circular Designs – Bridging Process Needs and Sustainability Goals

Authors

  • Michael U. Luescher Chemical & Analytical Development, Novartis Pharma AG, CH-4056 Basel, Switzerland.
  • Alessia Valotta Chemical & Analytical Development, Novartis Pharma AG, CH-4056 Basel, Switzerland.
  • Julien Haber Chemical & Analytical Development, Novartis Pharma AG, CH-4056 Basel, Switzerland.
  • Fabrice Gallou Chemical & Analytical Development, Novartis Pharma AG, CH-4056 Basel, Switzerland.

DOI:

https://doi.org/10.2533/chimia.2025.606

PMID:

40936236

Keywords:

Circular economy, Distallation, LCA, Solvent selection, Sustainable process development

Abstract

Pharmaceutical industries play a crucial role in enhancing global health outcomes; however, like many other sectors, they also encounter significant environmental challenges. The extraction of raw materials and the manufacture of active pharmaceutical ingredients (APIs) result in considerable waste production, substantial resource consumption, and environmental pollution. Transitioning from traditional linear economic models to circular processes presents an opportunity for more sustainable pharmaceutical operations that benefit both communities and the environment. The circular economy framework – grounded in resource efficiency, waste minimization, and material regeneration – offers a path towards comprehensive sustainability in pharmaceutical practices. This is particularly relevant in the area of solvent usage, which accounts for over half the input mass and associated waste in most processes. This article examines the application of circular economy principles to solvent selection within process design, highlighting its significance as a central component of sustainable pharmaceutical development.

Downloads

Published

2025-09-10

How to Cite

[1]
M. U. Luescher, A. Valotta, J. Haber, F. Gallou, Chimia 2025, 79, 606, DOI: 10.2533/chimia.2025.606.